Last edition
News about Market
US Food and Drug Administration Clears Expanded Access Pathway for Daraxonrasib
Regulator issues “safe to proceed” letter to Revolution Medicines, enabling early patient access to investigational therapy for advanced pancreatic cancer.
Market | 04/05/2026 | By News Bureau | 557
Vanda Pharmaceuticals Launches NEREUS (tradipitant) for Motion Sickness in US
Vanda Pharmaceuticals launches NEREUS (tradipitant), the first new motion sickness treatment in over 40 years, now available in the US with direct ordering via nereus.us.
Market | 04/05/2026 | By News Bureau | 189
Novelty Nobility Partners with AGC Biologics to Advance Bispecific Drug Candidate
Novelty Nobility partners with AGC Biologics to advance a bispecific Antibody Drug Candidate (ADC) into GMP manufacturing, showcasing Japan’s bioprocessing expertise and AGC Biologics’ global development network.
Market | 04/05/2026 | By News Bureau | 172
Indoco Remedies Transfers Ophthalmic Division to Sunways India
Indoco Remedies transfers its ophthalmic business in India and select African markets to Sunways India under a strategic business transfer agreement to strengthen portfolio focus and growth.
Market | 02/05/2026 | By News Bureau | 486
U.S. Food and Drug Administration grants Priority Review and Breakthrough Therapy status to combination therapy showing significant survival benefits in advanced HER2-positive gastric and esophageal cancers.
Market | 01/05/2026 | By News Bureau | 135
Parexel Acquires Vitrana to Boost Patient Safety Solutions
Parexel acquires Vitrana to enhance patient safety solutions with an Artificial Intelligence (AI)-enabled platform offering integrated pharmacovigilance, improved efficiency, and stronger regulatory compliance.
Market | 01/05/2026 | By News Bureau | 328
Chiesi Group to Acquire KalVista Pharmaceuticals to Expand Rare Disease Portfolio
Chiesi Group to acquire KalVista Pharmaceuticals for USD 1.9 billion, adding an oral on-demand therapy for hereditary angioedema and strengthening its global rare disease portfolio, with closing expected in Q3 2026.
Market | 30/04/2026 | By News Bureau | 207
Gilead Sciences Completes Arcellx Inc. Acquisition Ahead of Anito-cel Launch
Under the terms of the transaction, Gilead acquired Arcellx for USD 115 per share in cash, plus one non?transferable Contingent Value Right (CVR) of USD 5 per share, representing a total implied equity value of approximately USD 7.8 billion at the time of closing.
Market | 29/04/2026 | By News Bureau | 212
Thermo Fisher to Sell Microbiology Business to Astorg in USD 1.07 Billion Deal
Thermo Fisher’s microbiology business, which generated USD 645 million in 2025 revenue, will transition to Astorg as part of a strategic portfolio realignment.
Market | 29/04/2026 | By News Bureau | 331
Akums Launches Aztreonam-Avibactam to Combat Drug-Resistant Infections
Akums launches Aztreonam-Avibactam, an advanced antibiotic for severe drug-resistant infections, offering a new treatment option for life-threatening infections in intensive care settings.
Market | 29/04/2026 | By News Bureau | 313
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy